CTLA4 and melanoma: Puzanov et al. reported the findings of a Phase Ib trial of T-VEC in combination with ipilimumab (a cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) checkpoint inhibitor) in patients with advanced melanoma [14].